Chairman & CEO, Eisai Inc. Neurology Business Group President & Global Alzheimer’s Disease Officer, Eisai Co., Ltd.
Ivan Cheung concurrently serves as Chairman and CEO of Eisai Inc. in the United States, as well as the Global President of Eisai’s Neurology Business Group. In the latter role, he is responsible for Eisai’s global end-to-end activities
Ivan Cheung concurrently serves as Chairman and CEO of Eisai Inc. in the United States, as well as the Global President of Eisai’s Neurology Business Group. In the latter role, he is responsible for Eisai’s global end-to-end activities from discovery research and clinical development to brand commercialization and business development across Alzheimer’s disease & dementia, epilepsy, sleep-wake rhythm and neurodegenerative diseases. He is also a Senior Corporate Officer for Eisai Co., Ltd. in Japan, the parent company of Eisai Inc.
Since joining Eisai Co., Ltd. in 2005, Ivan has held positions of rising responsibility across corporate planning & strategy, corporate finance, talent management, global R&D, the U.S. commercial business, the Japan consumer healthcare business, the global oncology business and the global neurology business. Prior to joining Eisai, he was with the Global Health Practice at Booz Allen Hamilton, where he provided strategy and operations consulting to biopharmaceutical and healthcare clients in the U.S., Europe and Asia.
Ivan received his MBA from Harvard Business School, and earned a Bachelor of Science degree in Civil/Environmental Engineering with a double major in Economics from Duke University. He is a Board member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO), as well as Board chairman of KAN Research Institute in Kobe, Japan.